VIVA BIOTECH1873.HKValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 16, 2026, VIVA BIOTECH (1873.HK) trades at a P/E of 14.10x, P/B of 0.63x, P/S of 1.32x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E sits at the 14th percentile over the trailing 10Y window (vs. 27th percentile over 3Y); P/B sits at the 23rd percentile over the trailing 10Y window (vs. 50th percentile over 3Y); P/S sits at the 33rd percentile over the trailing 10Y window (vs. 48th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 42nd percentile within its industry and the 61st percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 1.65%, ranking at the 90th percentile over the trailing 20Y window.
The P/E and P/B long-window percentiles differ by only 8.4 points, pointing to a consistent valuation read across both metrics. Relative to industry peers, its P/E shows a deeper discount than it does against the broader market. Shareholder returns here lean heavily on buybacks rather than cash dividends. VIVA BIOTECH operates in the Biomedical II sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: HKG: 1873 · SEHK: 1873 · 1873
Want the full picture on whether VIVA BIOTECH (1873.HK) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 14.10 | ||||||
| P/B (MRQ) | 0.63 | ||||||
| P/S (TTM) | 1.32 | ||||||
| Dividend Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback + Div Yield | 1.65% |